Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

60.10 -1.08 (-1.77%)

Streaming Delayed Price Updated: 12:01 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9

...

44 45 Next >

Deadline Soon: GSK plc. (GSK) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

April 04, 2025

From Law Offices of Frank R. Cruz

Via Business Wire

New Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops ↗

April 03, 2025

A study of over 280,000 adults found that the shingles vaccine reduced dementia risk by 20%, with a stronger effect in women.

Via Benzinga

GSK Deadline: Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

April 03, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Peering Into GSK's Recent Short Interest ↗

February 24, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK

April 03, 2025

From Pomerantz LLP

Via GlobeNewswire

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK

April 02, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK

March 30, 2025

From Pomerantz LLP

Via GlobeNewswire

Looking Into GSK's Recent Short Interest ↗

March 26, 2025

Via Benzinga

FDA Approves GSK's Oral Antibiotic For Urinary Tract Infections For Females Aged 12 Years And Older ↗

March 26, 2025

The FDA approved GSK's Blujepa for uncomplicated UTIs in female adults and pediatric patients, with phase 3 trials showing strong efficacy vs. nitrofurantoin.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK

March 26, 2025

From Pomerantz LLP

Via GlobeNewswire

Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older

March 25, 2025

From GSK plc

Via Business Wire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK

March 24, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK

March 23, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK

March 21, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion ↗

March 19, 2025

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%.

Via Benzinga

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides ↗

March 19, 2025

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the...

Via Benzinga

Topics Government

GSK Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About How to Lead the GSK PLC Class Action

March 18, 2025

From Robbins LLP

Via GlobeNewswire

GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study ↗

March 12, 2025

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early data on VH184 and VH499 therapies.

Via Benzinga

Why Moderna Stock Has Surged 20% This Week Despite Mixed News ↗

March 07, 2025

Recent news has been mixed with a patent win and loss in Germany and the U.S. But Moderna stock has risen markedly this week.

Via Investor's Business Daily

Topics Intellectual Property

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 ↗

March 06, 2025

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.

Via Benzinga

Topics Earnings

GSK's Once-Daily Inhalers For Smoker's Lung Has Potential Benefits: Independent Organization Report ↗

March 04, 2025

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

Via Benzinga

GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review ↗

March 03, 2025

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements.

Via Benzinga

Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis ↗

March 03, 2025

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Via Benzinga

Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds ↗

February 27, 2025

Moderna is under pressure as two of its vaccines hit potential snags.

Via Investor's Business Daily

Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025 ↗

February 27, 2025

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.

Via Benzinga

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK

February 25, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week ↗

February 18, 2025

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage recommendations on Feb. 26.

Via Benzinga

GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 17, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors ↗

February 17, 2025

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.

Via Benzinga

PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY

February 17, 2025

From GSK plc

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.